Author

Dapo Ilo 1

1 AbbVie Inc.,Chicago,United States;;

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

Marla C. Dubinsky, MIn A. Yang, Mirko Fillbrunn, Silvio Danese, Johan Burisch, Satoshi Tanida, Dolly Sharma, Dapo Ilo, Wen Zhou, Yuri Sanchez Gonzalez, Laurent Peyrin-Biroulet

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

Julian Panés, Peter Higgins, Edward Loftus Jr., James Lindsay, Yuir Sanchez Gonzalez, Wen Zhou, Qing Zhou, Dapo Ilo, Charles Phillips, Severine Vermeire

Item 11 - 12 / 12
1
2